GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Palatin Technologies
Palatin Technologies is a biopharmaceutical company focused on treating diseases involving melanocortin receptors. Its stock price reflects both sales of its women's health drug and the hopes for the success of its new developments.
Share prices of companies in the market segment - Pharma women
Palatin Technologies is a biopharmaceutical company specializing in the development of melanocortin receptor-targeted drugs for the treatment of female sexual dysfunction and other conditions. We've categorized it as "Pharma: Women." The chart below shows the market dynamics in this niche.
Broad Market Index - GURU.Markets
Palatin Technologies is a biopharmaceutical company specializing in the development of melanocortin receptor-targeted drugs for the treatment of female sexual dysfunction and other conditions. We've categorized it as "Pharma: Women." The chart below shows the market dynamics in this niche.
Change in the price of a company, segment, and market as a whole per day
PTN - Daily change in the company's share price Palatin Technologies
Palatin Technologies, Inc.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures its sensitivity to sales of its drug for women and news about clinical trials.
Daily change in the price of a set of shares in a market segment - Pharma women
Palatin Technologies develops drugs targeting melanocortin receptors to treat various conditions, including female sexual dysfunction. This is a highly specialized and risky niche. The chart below shows the volatility in the pharmaceutical sector, reflecting these risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Palatin Technologies is a pharmaceutical company focused on women's health. Its shares are highly volatile and depend on the results of clinical trials and the commercial success of its drugs. These scientifically based movements are part of the complex picture of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Palatin Technologies
For Palatin Technologies, year-over-year performance is the story of its women's health drug. Its market cap change over the past 12 months reflects the success of commercializing its Vyleesi drug for hypoactive sexual desire disorder. Its valuation is a bet that this niche product will find its audience.
Annual dynamics of market capitalization of the market segment - Pharma women
Palatin, a late-stage biotech company, develops drugs for the treatment of inflammatory diseases and women's health. Its stock performance is entirely dependent on clinical trial results and commercial success. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Palatin Technologies, focused on women's health, demonstrates the success of its commercial strategy with its growth. Unlike developers, it already sells its products. Its ability to outperform the market is directly dependent on revenue growth and its ability to compete in its pharmaceutical niche.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Palatin Technologies
Palatin is a biopharmaceutical company with a commercial product for women's health. Its monthly performance reflects both sales of this drug and progress in its clinical programs for the treatment of inflammatory diseases.
Monthly dynamics of market capitalization of the market segment - Pharma women
Palatin Technologies specializes in developing melanocortin receptor-acting drugs for the treatment of conditions with unmet medical needs, including female sexual dysfunction. The chart below illustrates the overall dynamics of the women's health sector, which has historically been underfunded but is now attracting increasing attention.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies with niche products can move on their own news, ignoring the market. The chart below shows the general trends. Is Palatin Technologies living its own life, where success is determined by FDA decisions and the commercial potential of its drugs?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Palatin Technologies
Palatin, a biopharmaceutical company focused on treating female sexual dysfunction, shares reflect the state of this niche market on a weekly basis. Its stock price responds to sales of its drug and progress in developing new drugs.
Weekly dynamics of market capitalization of the market segment - Pharma women
Palatin Technologies develops drugs targeting melanocortin receptors for the treatment of various diseases. This chart will help separate its own news-driven dynamics from the overall pharma sector, demonstrating how the market values its unique scientific platform.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Palatin Technologies is a biopharmaceutical company. Its success depends on the results of clinical trials. This chart will help you understand: does Palatin live in its own world of scientific news, or are the overall market conditions and risk appetite actually influencing its stock price?
Market capitalization of the company, segment and market as a whole
PTN - Market capitalization of the company Palatin Technologies
Palatin's market capitalization tells the story of a biotech company focused on treating diseases involving melanocortin receptors. The chart reflects the commercialization of its female sexual health drug and hopes for new products. Its dynamics tell the story of its quest for a blockbuster.
PTN - Share of the company's market capitalization Palatin Technologies within the market segment - Pharma women
Palatin Technologies focuses on developing drugs to treat diseases with unmet medical needs. Its share of its segment's market capitalization reflects the market valuation of its developments. The chart shows how its share changes as drugs progress through clinical trials.
Market capitalization of the market segment - Pharma women
Palatin Technologies is a biopharmaceutical company specializing in drugs for the treatment of diseases with unmet medical needs. The chart below shows the overall market capitalization of this sector. Its dynamics provide the backdrop against which Palatin is attempting to commercialize its niche products.
Market capitalization of all companies included in a broad market index - GURU.Markets
Palatin Technologies develops drugs to treat conditions for which there are few effective treatments, particularly in women's health. Its market capitalization reflects the hope that its research will lead to the development of in-demand drugs. Its performance reflects how the market views its niche strategy.
Book value capitalization of the company, segment and market as a whole
PTN - Book value capitalization of the company Palatin Technologies
Palatin Technologies' foundation is its capital, which is dedicated to the development and commercialization of drugs for conditions where other treatments are ineffective, such as women's sexual health. This is a tangible, scientific foundation for niche but important medical needs. How has this asset changed? The chart below shows its dynamics.
PTN - Share of the company's book capitalization Palatin Technologies within the market segment - Pharma women
Palatin Technologies develops drugs targeting melanocortin receptors to treat various diseases. The chart shows the share of its R&D assets, reflecting the physical foundation of its scientific work in this niche area.
Market segment balance sheet capitalization - Pharma women
Palatin, a biopharmaceutical company, has a moderately capital-intensive business. This requires ownership of R&D and control over the production of its drugs. The BCap_Seg chart for the biotech sector shows that commercial success requires a substantial financial base.
Book value of all companies included in the broad market index - GURU.Markets
Palatin's book value is derived from its commercial drug Vyleesi for female sexual dysfunction and its pipeline of developments for the treatment of inflammatory diseases. The company's assets are its intellectual property. The chart below shows how this biotech business compares in terms of asset size.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Palatin Technologies
Palatin Technologies develops drugs that target specific receptors in the body. Its balance sheet is based on research expenditures. Its market capitalization reflects its belief in its scientific approach and the commercial potential of its approved and future products, particularly for the treatment of female sexual dysfunction.
Market to book capitalization ratio in a market segment - Pharma women
Palatin Technologies develops drugs targeting melanocortin receptors for the treatment of various diseases. Its market valuation on the chart reflects both the commercial potential of its approved drug and the speculative interest in its research pipeline.
Market to book capitalization ratio for the market as a whole
Palatin Technologies focuses on developing drugs for specific needs, such as women's health. The company's value is determined by its intellectual property. This chart allows investors to see how expectations for niche biopharmaceutical companies differ from the general market sentiment.
Debts of the company, segment and market as a whole
PTN - Company debts Palatin Technologies
Palatin Technologies, a biopharmaceutical company focused on developing drugs that target the melanocortin system, uses capital to fund its clinical trials. This chart shows how the company manages its resources to commercialize its niche products and expand their use.
Market segment debts - Pharma women
Palatin Technologies is a biotechnology company focused on developing drugs to treat diseases with unmet medical needs, particularly in women's health. This chart shows how the company funds its clinical research and commercial efforts, balancing equity and possible debt.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Palatin Technologies
Palatin Technologies specializes in drugs for the treatment of diseases with unmet medical needs, particularly in women's health. This chart shows the company's reliance on debt to fund its clinical trials, a key indicator of its financial risk.
Market segment debt to market segment book capitalization - Pharma women
Palatin Technologies develops drugs to treat melanocortin-related disorders, including female sexual dysfunction and inflammatory diseases. The chart shows the overall debt burden in the pharmaceutical industry, providing context for how Palatin finances its niche yet complex clinical programs.
Debt to book value of all companies in the market
Palatin Technologies, a biopharmaceutical company focused on treating diseases with unmet medical needs, requires significant investments in R&D. This chart, reflecting the overall market debt load, provides context. It helps understand how its financial strategy is typical for biotech companies on the path to commercialization of new products.
P/E of the company, segment and market as a whole
P/E - Palatin Technologies
Palatin Technologies develops drugs targeting the melanocortin system to treat conditions with unmet medical needs, including female sexual dysfunction. This chart shows how the market is assessing its niche developments. This assessment depends on the success of its drugs in clinical trials and their commercial potential.
P/E of the market segment - Pharma women
Palatin's specialty, treating female sexual dysfunction, is a niche pharmaceutical. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Palatin is evaluated based on the potential of its products to fill a niche in a market considered complex and sensitive.
P/E of the market as a whole
Palatin Technologies is a biopharmaceutical company specializing in developing drugs to treat diseases with unmet medical needs. Its valuation is entirely dependent on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Palatin Technologies
For Palatin Technologies, Inc., a biopharmaceutical company developing drugs to treat conditions with unmet medical needs, this chart shows market expectations for its products. It reflects sales forecasts for its women's health drug and the success of its other developments.
%20P%2FE%20Palatin%20Technologies&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Palatin-Technologies&v=1772643213464 "Chart of the company's future (projected) P/E Palatin Technologies")
Future (projected) P/E of the market segment - Pharma women
Palatin Technologies specializes in developing melanocortin receptor-targeted drugs for the treatment of conditions with unmet medical needs, including female sexual dysfunction. The chart shows industry forecasts, helping to assess how the market perceives the commercial potential of Palatin's niche products and its scientific platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20women&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-women&v=1772643213507 "Future (projected) P/E graph of the market segment - Pharma women")
Future (projected) P/E of the market as a whole
Palatin Technologies, Inc. is a biopharmaceutical company specializing in developing drugs to treat diseases for which there are no effective treatments, such as women's health. Success depends on the commercialization of niche products. This graph of overall market sentiment influences the valuation of these specialized companies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772643213533 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Palatin Technologies
Palatin Technologies specializes in developing melanocortin receptor-targeted drugs for the treatment of diseases with unmet medical needs, including women's health. This chart shows the company's financial progression from research to commercialization of niche pharmaceutical products.
Profit of companies in the market segment - Pharma women
Palatin Technologies specializes in developing melanocortin receptor-acting drugs to treat conditions with unmet needs. This chart, which shows profitability in the pharmaceutical sector, demonstrates the importance of specialization. Their drug, Vyleesi, is designed to treat female sexual desire disorders, occupying a unique niche in the market.
Overall market profit
Palatin Technologies specializes in developing melanocortin receptor-targeted drugs for the treatment of conditions with unmet medical needs, particularly in women's health. The company's success depends on clinical trial results. This gross profitability chart reflects the investment climate essential for funding such niche developments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Palatin Technologies
Palatin Technologies specializes in developing melanocortin receptor-targeted drugs for the treatment of conditions with unmet medical needs, including female sexual dysfunction. This chart reflects analysts' sales forecasts for the currently approved product and the potential for future developments.
%20profit%20of%20the%20company%20Palatin%20Technologies&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Palatin-Technologies&v=1772643213738 "Graph of future (projected) profit of the company Palatin Technologies")
Future (predicted) profit of companies in the market segment - Pharma women
Palatin Technologies is a biopharmaceutical company specializing in the development of melanocortin receptor-targeted drugs for the treatment of conditions with unmet medical needs, including female sexual dysfunction. This pharmaceutical sector chart provides context for assessing the potential of niche but important therapeutic areas.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20women&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-women&v=1772643213786 "Graph of future (predicted) profits of companies in a market segment - Pharma women")
Future (predicted) profit of the market as a whole
Palatin Technologies develops drugs to treat conditions with unmet medical needs, including women's health. The company's success depends on science. The overall profit forecast reflected here influences the willingness of major pharmaceutical companies to partner with them and influences investor sentiment.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772643213806 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Palatin Technologies
Palatin Technologies specializes in developing melanocortin receptor-targeted drugs for the treatment of diseases with unmet medical needs. The chart shows how investors estimate the revenue of its commercial product for women. It reflects the potential of its lead drug and other developments.
P/S market segment - Pharma women
Palatin Technologies specializes in developing melanocortin receptor-targeted drugs for the treatment of diseases with unmet medical needs, including women's health. The company's revenue depends on the success of its developments. This chart helps understand how investors view Palatin's niche scientific specialization and commercial prospects.
P/S of the market as a whole
Palatin Technologies is a biopharmaceutical company focused on developing melanocortin receptor-targeted drugs for the treatment of conditions with unmet medical needs, including female sexual dysfunction. This chart, showing the average market revenue estimate, serves as a benchmark for Palatin.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Palatin Technologies
Palatin Technologies is a biopharmaceutical company specializing in the development of drugs targeting the melanocortin system, with a focus on the treatment of female sexual dysfunction and inflammatory diseases. This chart reflects investor expectations for the future commercial success of its drugs in these challenging but potentially large markets.
%20P%2FS%20Palatin%20Technologies&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Palatin-Technologies&v=1772643213901 "The graph of the company's future (projected) P/S Palatin Technologies")
Future (projected) P/S of the market segment - Pharma women
Palatin Technologies, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for the treatment of diseases with unmet medical needs, particularly in women's health. This chart reflects average revenue expectations in the pharmaceutical sector. It provides an insight into the market perception of the potential of Palatin's products.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20women&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-women&v=1772643213906 "Future (projected) P/S market segment graph - Pharma women")
Future (projected) P/S of the market as a whole
Palatin Technologies specializes in developing melanocortin receptor-targeted drugs for the treatment of conditions with unmet medical needs, including women's health. This chart shows the market's collective revenue expectations. The company's success could bring new treatments to market for understudied conditions.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772643213920 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Palatin Technologies
This chart shows the sales of Palatin Technologies, a biopharmaceutical company. Its primary source of revenue is sales of Vyleesi, a drug designed to treat female sexual desire disorders. The trend reflects the commercial success of this product and revenue from other licensing agreements.
Sales of companies in the market segment - Pharma women
Palatin Technologies specializes in developing melanocortin receptor-targeted drugs for the treatment of conditions with unmet medical needs, including female sexual dysfunction. This chart shows revenue in niche pharmaceutical market segments. Palatin's success in this complex area demonstrates the potential for creating new markets.
Overall market sales
Palatin Technologies develops drugs to treat conditions with unmet medical needs, including women's health. Its success depends on regulatory approval. The overall economic situation, shown in this chart, influences healthcare funding and the commercialization of new drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Palatin Technologies
Palatin Technologies specializes in developing drugs to treat conditions with significant unmet needs, including female sexual dysfunction. Future revenue depends on sales of its niche products. The chart shows the forecast for these specific markets.
%20sales%20of%20the%20company%20Palatin%20Technologies&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Palatin-Technologies&v=1772643214049 "Schedule of future (projected) sales of the company Palatin Technologies")
Future (projected) sales of companies in the market segment - Pharma women
Palatin Technologies specializes in developing melanocortin receptor-targeted drugs for the treatment of conditions with unmet medical needs, particularly female sexual dysfunction. This chart shows the forecast for the entire pharmaceutical market, where Palatin operates in a complex but potentially significant niche.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20women&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-women&v=1772643214065 "Schedule of future (projected) sales of companies in the market segment - Pharma women")
Future (projected) sales of the market as a whole
Palatin Technologies is a biopharmaceutical company specializing in the development of drugs targeting the melanocortin system to treat diseases with unmet medical needs. This graph, reflecting the investment climate in biotechnology, impacts the company's ability to fund its research in niche but potentially profitable areas.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772643214106 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Palatin Technologies
Palatin Technologies specializes in developing melanocortin receptor-targeted drugs for the treatment of conditions with unmet medical needs, particularly female sexual dysfunction. This chart shows the company's financial results as it attempts to commercialize a product in a complex and sensitive therapeutic area.
Market segment marginality - Pharma women
Palatin Technologies is a biopharmaceutical company specializing in the development of melanocortin receptor-targeted drugs for the treatment of conditions with unmet medical needs, including women's health. Profitability depends on the commercial success of their products. This chart shows the financial performance of their niche pharmaceutical developments.
Market marginality as a whole
Palatin Technologies is a biopharmaceutical company focused on developing melanocortin receptor-targeted drugs for the treatment of diseases with unmet medical needs, including women's health. This overall profitability curve is not important to them. Their success depends on clinical data and the commercialization of their products.
Employees in the company, segment and market as a whole
Number of employees in the company Palatin Technologies
Palatin Technologies is a biopharmaceutical company specializing in the development of drugs targeting the melanocortin system. It operates with a small, focused team. This chart reflects its status as a development-stage company with one commercial product and several clinical programs.
Share of the company's employees Palatin Technologies within the market segment - Pharma women
Palatin Technologies focuses on developing drugs targeting the melanocortin system to treat conditions with unmet medical needs. This chart reflects its niche specialization. It demonstrates the size of the small but focused team that has successfully brought a women's health drug to market and continues research.
Number of employees in the market segment - Pharma women
Palatin Technologies, Inc. is a biopharmaceutical company specializing in the development of drugs targeting the melanocortin system to treat diseases with unmet medical needs. This chart reflects employment trends in a highly specialized pharmaceutical niche. The growth in the number of scientists here is driven by the commercialization of a drug for women's health.
Number of employees in the market as a whole
Palatin Technologies develops drugs targeting melanocortin receptors for the treatment of various diseases. The company's success depends on the results of clinical trials. A stable economic environment, reflected in this chart, is essential for raising the capital needed to conduct expensive and time-consuming research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Palatin Technologies (PTN)
Palatin Technologies is a biotech company focused on drugs that target melanocortin receptors (for example, for the treatment of female sexual dysfunction). It is an R&D company. The chart shows that the company's market value is based on its intellectual property. The high market capitalization per employee reflects that its small research team holds patents that could unlock a multibillion-dollar market.
%20of%20the%20company%20Palatin%20Technologies%20(PTN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Palatin-Technologies-PTN&v=1772643214632 "Chart of market capitalization per employee (in thousands of dollars) of the company Palatin Technologies (PTN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma women
Palatin Technologies is a biopharmaceutical company specializing in the development of drugs that target the melanocortin system to treat various conditions, including female sexual dysfunction. This chart shows how the market views the scientific potential and commercial prospects of its unique approach to drug development.
%20by%20market%20segment%20-%20Pharma%20women&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-women&v=1772643214682 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma women")
Market capitalization per employee (in thousands of dollars) for the overall market
Palatin Technologies specializes in developing drugs to treat conditions with significant unmet needs, including women's health. The chart shows the market's assessment of the niche pharmaceutical industry, reflecting how the market perceives the potential commercial success of their drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772643214803 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Palatin Technologies (PTN)
Palatin Technologies is a pharmaceutical company specializing in drugs that target melanocortin receptors. They already market Vyleesi (for female libido) and are developing others. It's a hybrid of R&D and commercialization. This graph illustrates the balance: revenue from Vyleesi should cover the costs of the R&D team.
%20Chart%20Palatin%20Technologies%20(PTN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Palatin-Technologies-PTN&v=1772643214828 "Company Profit Per Employee (in thousands of dollars) Chart Palatin Technologies (PTN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma women
Palatin Technologies is a biopharmaceutical company whose drug Vyleesi is approved for the treatment of female sexual desire disorder. This figure reflects the challenging commercialization of a highly niche product, where marketing costs can exceed sales revenue.
%20in%20the%20market%20segment%20-%20Pharma%20women&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-women&v=1772643214860 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma women")
Profit per employee (in thousands of dollars) for the market as a whole
Palatin Technologies (PTN) is a biopharmaceutical company with an approved drug (Vyleesi) for the treatment of female sexual dysfunction. It's a single-product business. This chart shows how successfully (or not) the company's sales team is selling this niche, difficult-to-market drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772643214900 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Palatin Technologies (PTN)
Palatin Technologies specializes in developing drugs that target melanocortin receptors for the treatment of various diseases. This chart shows the commercial potential of its developments. Revenue per employee growth will reflect successful sales of approved drugs, such as those for the treatment of female sexual dysfunction.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Palatin-Technologies-PTN&v=1772643214928 "Sales chart per company employee Palatin Technologies (PTN)")
Sales per employee in the market segment - Pharma women
Palatin Technologies (PTN) is a pharmaceutical company focused on melanocortin receptor-acting drugs. Their flagship product, Vyleesi, is approved for the treatment of female sexual dysfunction. This chart shows the revenue generated by each employee from sales of this niche drug.
Sales per employee for the market as a whole
Palatin Technologies (PTN) is a pharmaceutical company focused on drugs that target melanocortin receptors. The company has an approved drug (Vyleesi) for the treatment of female sexual dysfunction. This chart shows how successfully the company (and its partners) generate revenue (royalties) from sales of its niche product.
Short shares by company, segment and market as a whole
Shares shorted by company Palatin Technologies (PTN)
Palatin Technologies has one approved product, Vyleesi, for the treatment of low sexual desire in women. This chart shows bearish bets. Investors are shorting the stock because the commercial launch of Vyleesi is considered a complete failure, and the company has no other strong assets in development.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Palatin-Technologies-PTN&v=1772643215203 "Short Shares Chart for the Company Palatin Technologies (PTN)")
Shares shorted by market segment - Pharma women
Palatin Technologies (PTN) is a biopharmaceutical company focused on developing drugs that modulate the melanocortin system. Their key drug, Vyleesi, targets the women's health market. This indicator measures the total volume of short positions across the entire specialty pharmaceutical sector. It reveals the extent to which investors are skeptical of the commercial success of lifestyle drugs across the industry.
Shares shorted by the overall market
Palatin is a biotech with a niche focus (women's health). This chart illustrates the overall market pessimism. When investors are fearful, they're unwilling to fund "long-term science." They see an R&D company without stable revenue and sell off shares, fearing the money for research will run out.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Palatin Technologies (PTN)
Palatin Technologies is a biotech company focused on drugs for female sexual dysfunction (Vyleesi) and inflammatory diseases. This chart tracks how investors view the commercial launch of their drugs, showing "overbought" (above 70) on positive sales reports or "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Palatin-Technologies-PTN&v=1772643215406 "RSI 14 indicator chart for the company's stock Palatin Technologies (PTN)")
RSI 14 Market Segment - Pharma women
Palatin Technologies is a biopharmaceutical company specializing in the treatment of melanocortin receptor-related diseases. Their key product, Vyleesi, is a treatment for female sexual dysfunction. This chart reflects the overall sentiment in the biotech sector, helping to gauge how the market views this speculative industry.
RSI 14 for the overall market
Palatin (PTN) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PTN (Palatin Technologies)
Palatin (PTN) is a biopharmaceutical company whose key approved drug, Vyleesi, is designed to treat female hypoactive sexual desire disorder. This chart shows the average 12-month forecast. It reflects analyst expectations for the commercial success of Vyleesi and the potential of its scientific platform in other therapeutic areas.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PTN-Palatin-Technologies&v=1772643215456 "A chart showing analyst consensus forecasts for the expected stock price. PTN (Palatin Technologies)")
The difference between the consensus estimate and the actual stock price PTN (Palatin Technologies)
Palatin (PTN) is a biotech company focused on treating sexual dysfunction (Vyleesi – "female Viagra") and inflammatory diseases. This chart shows analysts' forecasts for the stock's upside and downside. It measures the gap between the price and forecast, reflecting their view of this complex R&D market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PTN-Palatin-Technologies&v=1772643215492 "A chart showing the difference between the consensus forecast and the actual stock price. PTN (Palatin Technologies)")
Analyst consensus forecast for stock prices by market segment - Pharma women
Palatin is a biotech focused on libido. Its lead product (Vyleesi) is an FDA-approved treatment for low sexual desire in women. This chart displays analysts' overall expectations for the *entire* female pharma sector. It shows whether experts believe this niche will be commercially successful.
Analysts' consensus forecast for the overall market share price
Palatin Technologies (PTN) is a biopharmaceutical company focused on women's health. Their key product (Vyleesi) is a treatment for low libido in women. This is a complex lifestyle market. This chart shows the overall risk appetite. It reflects the market's willingness to fund R&D projects in low-hype, yet important, areas of medicine.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Palatin Technologies
Palatin is a biotech receptor hunter. Their specialty is the R&D of drugs (melanocortins) that modulate these receptors to treat inflammation (dry eye) and sexual dysfunction (Vyleesi). This chart is a summary of their R&D model. It reflects their (meager) royalties from Vyleesi and their (very risky) R&D pipeline.
AKIMA Market Segment Index - Pharma women
Palatin Technologies (PTN) is a pharmaceutical company focused on women's (and men's) health. Their key product is Vyleesi, a treatment for low sexual desire in women. This chart compares their composite index to the sector, showing how their niche R&D strategy outperforms their competitors.
The AKIM Index for the overall market
Palatin Technologies is a biopharmaceutical company developing peptide drugs for the treatment of melanocortin-related disorders (dry eye, sexual health). This chart, which reflects the market average, provides a macro backdrop. It helps assess how Palatin Technologies, which is commercializing Vyleesi, compares to overall trends.
